Cardiovascular Drugs and Therapy

, Volume 25, Issue 6, pp 531–537 | Cite as

Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina

  • E. Amosova
  • E. Andrejev
  • I. Zaderey
  • U. Rudenko
  • C. Ceconi
  • R. Ferrari



The antianginal and anti-ischemic efficacy of the selective I f inhibitor ivabradine is established in patients with stable angina in monotherapy and in combination with other antianginals, including beta-blocker. This pilot study compared the antianginal and anti-ischemic efficacy and hemodynamic profile of ivabradine plus 5 mg bisoprolol versus those of 10 mg bisoprolol in patients with stable angina.

Patients and methods

Twenty-nine patients with stable angina and moderate left ventricular systolic dysfunction already on bisoprolol 5 mg od were randomized into 2 groups. Group 1 (n = 17) received ivabradine (5–7.5 mg bid) in addition to bisoprolol 5 mg od, while in group 2 (n = 12) bisoprolol was uptitrated first to 7.5 mg and then 10 mg od. Patients underwent a treadmill test, 6-minute walking test, and echocardiography at baseline and after 2 months.


Mean resting heart rate decreased in both groups, from 76.6 ± 4.6 bpm to 59.3 ± 2.5 bpm (P < 0.001) in group 1 and from 75.9 ± 3.0 bpm to 60.5 ± 2.3 bpm (P = 0.002) in group 2. The effect on resting heart rate did not differ significantly between the two groups. However, more patients became asymptomatic in group 1 than in group 2. Addition of ivabradine also improved exercise capacity, as shown by the results of the 6-minute walking and exercise tolerance tests, whereas in group 2 neither parameter was significantly affected. Chronotropic reserve significantly improved with ivabradine, but not with bisoprolol 10 mg.


These results suggest that combining ivabradine with low dose bisoprolol in stable angina patients produces additional antianginal and anti-ischemic benefits and improves chronotropic reserve.

Key words

Ivabradine Bisoprolol Combination therapy Stable angina Coronary artery disease Left ventricular dysfunction Exercise tolerance 


  1. 1.
    Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–30.PubMedCrossRefGoogle Scholar
  2. 2.
    DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53:399–406.PubMedCrossRefGoogle Scholar
  3. 3.
    Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393–405.PubMedCrossRefGoogle Scholar
  5. 5.
    Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet. 2010;376:875–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–67.PubMedGoogle Scholar
  11. 11.
    Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pellikka PA. Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. J Am Coll Cardiol. 2003;42:823–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Witte KK, Cleland JG, Clark AL. Chronic heart failure, chronotropic incompetence, and the effects of beta blockade. Heart. 2006;92:481–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Villella M, Villella A, Barlera S, Franzosi MG, Maggioni AP. Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI-2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell-Infarto Miocardico. Am Heart J. 1999;137:443–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–66.PubMedGoogle Scholar
  16. 16.
    Baumgart D, Haude M, Gorge G, et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090–7.PubMedGoogle Scholar
  17. 17.
    Heusch G, Baumgart D, Camici P, et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689–94.PubMedGoogle Scholar
  18. 18.
    Ceconi C, Comini L, Suffredini S, et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2011;300:H366–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Ceconi C, Freedman SB, Tardif JC, et al. Effect of heart rate redution by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146:408–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • E. Amosova
    • 1
  • E. Andrejev
    • 1
  • I. Zaderey
    • 1
  • U. Rudenko
    • 1
  • C. Ceconi
    • 2
    • 3
  • R. Ferrari
    • 4
  1. 1.National Medical UniversityKievUkraine
  2. 2.Department of CardiologyUniversity of FerraraFerraraItaly
  3. 3.Salvatore Maugeri FoundationIRCCSLumezzaneItaly
  4. 4.Department of Cardiology and LTTA CentreUniversity Hospital of Ferrara and Salvatore Maugeri Foundation, IRCCSLumezzaneItaly

Personalised recommendations